Indeed, somatic mutations of the p85α:p110α interface disrupt the inhibitory action of p85α on bound p110α leading to PI3K pathway activation in cancers (Miled et al., 2007; Jaiswal et al., 2009). The gene discussed is PIK3CA; the disease is cancer.